Type 1 diabetes
Altheia Science S.r.l. is engaged in clinical research focused on type 1 diabetes, with interest in early disease management and immune-related metabolic intervention.
- Autoimmune diabetes
- Early type 1 diabetes
- Glycemic regulation
The sponsor’s research activity in this area reflects attention to therapeutic strategies aimed at preserving pancreatic function and addressing the underlying disease process in diabetes mellitus.
Gene therapy
The sponsor’s clinical research includes gene therapy approaches for metabolic disease, with a particular focus on interventions designed to modify disease biology in type 1 diabetes.
- Genetic medicine
- Targeted molecular therapy
- Cell-based gene intervention
Its therapeutic interests extend to treatment concepts that use genetic modification to support disease-specific biological correction.
Stem cell therapy
Altheia Science S.r.l. is also involved in research using patient-derived stem cells, linking regenerative medicine with endocrine and metabolic applications.
- Autologous stem cells
- Regenerative medicine
- Cellular therapy
This area of interest centers on cellular approaches intended to support tissue repair and functional restoration in pancreatic disorders.
Safety evaluation
The sponsor’s active trial portfolio places emphasis on treatment safety in a first-in-human setting, with attention to tolerability in a novel therapeutic context.
- Clinical safety
- Therapeutic tolerability
- Human translational research
Its research activity is concentrated in Milan, Italy, within a single ongoing study in Europe.
